Pharmacological Management of Insomnia

Initial Treatment Approach

The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment approach for primary chronic insomnia, with medication used as a supplement when necessary 1, 2, 3
Sleep hygiene alone is insufficient but should be combined with other therapies, according to the American Academy of Sleep Medicine 1, 3
Stimulus control therapy, relaxation therapy, or multicomponent CBT-I are standard initial behavioral approaches, as suggested by the American Academy of Sleep Medicine 1

The American Academy of Sleep Medicine recommends short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) or ramelteon as first-line pharmacological agents for primary chronic insomnia 1, 2, 4
Zolpidem 10 mg is effective for both sleep onset and maintenance insomnia, with demonstrated superiority over placebo on sleep latency, duration, and efficiency, according to the American Academy of Sleep Medicine 5
Eszopiclone 2-3 mg is effective for both sleep onset and maintenance insomnia and is recommended by the American Academy of Sleep Medicine 5
Zaleplon 10 mg is specifically for sleep onset insomnia, with a shorter duration of action limiting its utility for maintenance issues, as noted by the American Academy of Sleep Medicine 5
Temazepam 15 mg is effective for both sleep onset and maintenance insomnia and is a traditional benzodiazepine option, according to the American Academy of Sleep Medicine 5
Ramelteon 8 mg is specifically for sleep onset insomnia and works as a melatonin receptor agonist without affecting GABA receptors, offering minimal cognitive risk, as suggested by the American Academy of Sleep Medicine and Praxis Medical Insights 3, 5

If initial BzRAs or ramelteon fail, the American Academy of Sleep Medicine recommends trying an alternate agent from the same class before moving to other drug categories 1, 2, 4
Sedating antidepressants become appropriate when treating concurrent psychiatric conditions, such as depression or anxiety, according to the American Academy of Sleep Medicine 1, 2, 4
Trazodone, amitriptyline, doxepin (higher doses), and mirtazapine are options for patients with comorbid depression or anxiety, as suggested by the American Academy of Sleep Medicine 1, 2, 4

The American Academy of Sleep Medicine explicitly recommends against the use of over-the-counter antihistamines (diphenhydramine) due to anticholinergic effects, lack of efficacy, and safety data 1, 2, 4, 5, 3
Melatonin 2 mg is not recommended due to insufficient evidence for efficacy, according to the American Academy of Sleep Medicine and Praxis Medical Insights 5, 3
Valerian and herbal supplements lack efficacy and safety data, as noted by the American Academy of Sleep Medicine 1, 2, 4, 5
Barbiturates and chloral hydrate are outdated with unacceptable safety profiles, according to the American Academy of Sleep Medicine 1, 2, 4
Tiagabine 4 mg and L-tryptophan 250 mg are not recommended due to insufficient benefit, as suggested by the American Academy of Sleep Medicine 5

Benzodiazepines carry a higher risk of amnesia, cognitive impairment, and potential contribution to dementia with long-term use, according to Praxis Medical Insights 3
Z-drugs (zolpidem, eszopiclone, zaleplon) also act on GABA receptors and carry cognitive side effect risks, as noted by Praxis Medical Insights 3
The American Academy of Sleep Medicine recommends using the lowest effective dose for the shortest necessary duration, with follow-up every few weeks initially to assess effectiveness, side effects, and ongoing need 2, 4, 3

The American Academy of Sleep Medicine suggests considering intermittent dosing (e.g., three nights per week) or as-needed use to reduce tolerance and dependence 2, 4, 3
Tapering medication when conditions allow, with CBT-I facilitating successful discontinuation, is recommended by the American Academy of Sleep Medicine 2, 4
Long-term use may be indicated for severe/refractory insomnia or chronic comorbid illness, but requires consistent follow-up, according to the American Academy of Sleep Medicine 2, 4

The American Academy of Sleep Medicine recommends that all pharmacological treatment include education about treatment goals, realistic expectations, safety concerns, potential side effects, drug interactions, availability of cognitive-behavioral treatments, risk of dosage escalation, and potential for rebound insomnia upon discontinuation 1, 2, 4, 5, 3

The American Academy of Sleep Medicine suggests choosing medication based on symptom pattern, cognitive risk, comorbid conditions, past treatment responses, contraindications, drug interactions, patient preference, and cost 1, 2, 4
For sleep onset insomnia, zaleplon, zolpidem, ramelteon, or triazolam are recommended, according to the American Academy of Sleep Medicine 5
For sleep maintenance insomnia, eszopiclone, zolpidem, temazepam, suvorexant, or low-dose doxepin are recommended, as suggested by the American Academy of Sleep Medicine 5
For both onset and maintenance, eszopiclone, zolpidem, or temazepam are recommended, according to the American Academy of Sleep Medicine 5